Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of ET-743 (trabectedin) plus pegylated liposomal doxorubicin in recurrent ovarian-type cancers
jRCT2080223109Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Feb 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trabectedin and doxorubicin in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Taiho Pharmaceutical Co., Ltd. Started Feb 2016; status: completed.
02
Drugs
trabectedindoxorubicin
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2080223109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223109.